HPV and DNA markers in cervical cancer prognosis
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at whether certain markers in your blood (DNA from cancer cells and HPV) can help predict how well you do after first treatment for cervical cancer that has come back or spread. You would have extra blood draws during follow-up visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer that has come back or spread to other parts of the body (including first diagnosis at stage IVB).
- You completed standard first treatment with chemo and immunotherapy (with or without bevacizumab) and it worked completely.
- You are 18 years or older.
- You have not had any other cancer in the last 2 years.
- You are not pregnant or breastfeeding.
- You do not have serious heart, lung, liver, or kidney problems that are not controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial collects blood samples from women with HPV-related cervical cancer to see if a test can detect tiny bits of cancer DNA (molecular residual disease) and predict if the cancer might come back. Finding this DNA early could help guide future treatment decisions.
This study looks at whether monitoring HPV DNA in your blood after surgery can help predict if cervical cancer comes back, and whether this information can guide decisions about extra treatment. If you join, you'll provide blood samples before and after surgery to track your HPV levels.
This trial checks how well cervical cancer responds to surgery, radiation, and chemotherapy by measuring HPV DNA and RNA in blood and cervical mucus. It aims to improve monitoring during treatment.
This trial tests a personalized blood test that looks for tumor DNA to monitor cervical cancer and help guide treatment decisions. It is for people with advanced or returning cervical cancer who haven't started treatment yet.
This trial checks whether tumor samples contain HPV DNA (genetic material from the HPV virus). The goal is to improve detection in anal and cervical cancers, especially in patients planning standard radiation treatment.
This study looks for “methylated DNA markers” (special DNA patterns) to help detect endometrial, ovarian, and cervical cancers, and to support doctors around planned procedures. It may help find cancer earlier or better sort out who needs closer treatment.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.